Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae

Author： Tsukada Hiroki

Publisher： Springer Publishing Company

ISSN： 1341-321X

Source： Journal of Infection and Chemotherapy, Vol.18, Iss.5, 2012-10, pp. : 715-721

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Klebsiella pneumoniae is an important causative bacterium of aspiration pneumonia in many elderly patients. We retrospectively investigated the clinical effects of the early treatment of aspiration pneumonia and background factors in 24 patients from whom Klebsiella pneumoniae was isolated. Sulbactam/ampicillin (SBT/ABPC) was selected for early treatment in 12 of the 24 patients diagnosed with aspiration pneumonia, and tazobactam/piperacillin (TAZ/PIPC) was selected for the other patients. The effective rates and success rates of early treatment were significantly higher in the TAZ/PIPC group than in the SBT/ABPC group (p = 0.003 and 0.027, respectively). Although no significant difference was noted because of the limited number of cases, the survival rates after 30 days were 91.7 and 58.3 % in the TAZ/PIPC and SBT/ABPC groups, respectively. Several bacteria isolated with Klebsiella pneumoniae were resistant bacteria, such as methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa, and no anaerobe or extended-spectrum β-lactamase-producing Klebsiella pneumoniae was isolated. Thirteen and 11 of the 24 cases were classified as healthcare-associated pneumonia (HCAP) and hospital-acquired pneumonia (HAP), respectively, with no case classified as community-acquired pneumonia (CAP). As population aging progresses, the frequency of aspiration pneumonia classified as HCAP will increase. To cover anaerobes, it is necessary to select antibacterial drugs, such as TAZ/PIPC, for early treatment in consideration of resistant gram-negative bacteria to improve the outcome, and not drugs with weak activity against these bacteria.

Related content

Conjugative Resistance to Tazobactam Plus Piperacillin Among Extended-spectrum Beta-lactamase-producing Nosocomial Klebsiella pneumoniae

By Akhan Sila Çetin Coskunkan Figen Tansel Ozlem Vahaboglu Haluk

Scandinavian Journal of Infectious Diseases, Vol. 33, Iss. 7, 2001-07 ,pp. : 512-515 (4)

Informa Healthcare

Access to resources Recommend Favorite

Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan

By Kohno Shigeru Yanagihara Katsunori Yamamoto Yoshihiro Tokimatsu Issei Hiramatsu Kazufumi Higa Futoshi Tateyama Masao Fujita Jiro Kadota Jun-ichi

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1035-1041 (7)

Springer Publishing Company

Access to resources Recommend Favorite

Meningitis Caused by Streptococci Other than Streptococcus pneumoniae: a Retrospective Clinical Study

By Møller Kirsten Harder Frederiksen Eva Heugh Wandall Johan Skinhøj Peter

Scandinavian Journal of Infectious Diseases, Vol. 31, Iss. 4, 1999-09 ,pp. : 375-381 (7)

Informa Healthcare

Access to resources Recommend Favorite

Severe bone marrow suppression and hepatic dysfunction caused by piperacillin/tazobactam

By He Zhong-Fang Wu Xin-An Wang Yan-Ping

Scandinavian Journal of Infectious Diseases, Vol. 45, Iss. 11, 2013-11 ,pp. : 885-887 (3)

Informa Healthcare

Access to resources Recommend Favorite

Clinical characteristics of pneumonia caused by β-lactamase negative ampicillin resistant Haemophilus influenzae (BLNAR)

By Nakamura Shigeki Yanagihara Katsunori Seki Masafumi Izumikawa Koichi Higashiyama Yasuhito Miyazaki Yoshitsugu Hirakata Yoichi Mizuta Yohei Kohno Shigeru

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 6-7, 2007-01 ,pp. : 521-524 (4)

Informa Healthcare

Access to resources Recommend Favorite